31st week of 2014 patent applcation highlights part 52 |
Patent application number | Title | Published |
20140213582 | PRMT5 INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. | 2014-07-31 |
20140213583 | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone - Provided herein are methods for the treatment of bone cancer and prevention of the metastatic spread of cancer. | 2014-07-31 |
20140213584 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2014-07-31 |
20140213585 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES - This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): | 2014-07-31 |
20140213586 | VIRAL REPLICATION INHIBITORS - The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. | 2014-07-31 |
20140213587 | Biaryl Compositions and Methods for Modulating a Kinase Cascade - The invention relates to compounds and methods for modulating one or more components of a kinase cascade. | 2014-07-31 |
20140213588 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS - The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. The disclosure also provides a novel method of treating diseases or conditions related to the activity of endothelial lipase by use of compounds according to Formula (II): as defined in the specification and compositions comprising any of the compounds. | 2014-07-31 |
20140213589 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF - The invention relates to hydroxyphenyl derivatives of formula (I); and uses thereof as anti-bacterial and/or anti-parasitic agents. | 2014-07-31 |
20140213590 | CERTAIN DIPEPTIDYL PEPTIDASE INHIBITORS - Provided are certain dipeptidyl peptidase inhibitors, pharmaceutical compositions thereof, and methods of use therefor. | 2014-07-31 |
20140213591 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 2014-07-31 |
20140213592 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon - The present invention relates to the treatment of oncological, chronic inflammatory and similar diseases with the aid of new families of chemical compounds having improved efficiency with regard to the inhibition of Abl kinase and mutant forms thereof, as well as other therapeutically significant kinases. It describes protein kinase inhibitors in the form of compounds of general formula (I) and compounds of general formula (II), or a tautomer, an individual isomer, a mixture of isomers, a pharmaceutically acceptable salt, a solvate or a hydrate thereof. | 2014-07-31 |
20140213593 | BICYCLIC PYRAZOLE COMPOUNDS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to bicyclic pyrazole compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-07-31 |
20140213594 | ORGANIC COMPOUNDS - The present invention relates to compounds of formula (I) | 2014-07-31 |
20140213595 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2014-07-31 |
20140213596 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT - Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2014-07-31 |
20140213597 | Methods of Predicting and Treating Adverse Cardiac Events - The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject. | 2014-07-31 |
20140213598 | SUBSTITUTED CYANOANILINE COMPOUNDS, PREPARATION AND USE THEREOF - Disclosed is a substituted cyanoaniline compound or a salt thereof, wherein the compound has a structure represented by General Formula I. The compound of General Formula I has broad-spectrum fungicidal activity in the field of agriculture and effectively prevents against a variety of pathogens such as cucumber downy mildew, wheat powdery mildew, maize rust disease, rice blast and cucumber gray mold. In particular, even at a low dose, the compound effectively prevents and treats rice blast, cucumber gray mold, maize rust disease and cucumber downy mildew. Moreover, the raw materials for preparing the compounds are widely available and the synthesis method therefor is simple and convenient. | 2014-07-31 |
20140213599 | COMPOUNDS - The present invention relates to novel compounds that inhibit Lp-PLA | 2014-07-31 |
20140213600 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES - The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (HSV), and then administering to the human the compound anti-HSV agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (Neurodermatitis, Prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, Alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, Crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, Parkison's disease, anemia, cytopenia those among the diagnostic criteria. | 2014-07-31 |
20140213601 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 2014-07-31 |
20140213602 | ANTITUMOR AGENT AND THERAPEUTIC EFFECT PREDICTION METHOD FOR PATIENTS WITH KRAS-MUTATED COLORECTAL CANCER - This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, | 2014-07-31 |
20140213604 | PROTEIN KINASE C AS A TARGET FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS - The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC inhibitor and a pharmaceutically acceptable carrier. | 2014-07-31 |
20140213606 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2014-07-31 |
20140213607 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USINGDEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 2014-07-31 |
20140213608 | ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 2014-07-31 |
20140213609 | PROMOTING AXON RENEGERATION IN THE ADULT CNS THROUGH CONTROL OF PROTEIN TRANSLATION - Survival of, or axon regeneration in a lesioned mature central nervous system (CNS) neuron is promoted by (a) contacting the neuron with a therapeutically effective amount of an exogenous activator of protein translation; and (b) detecting the resultant promotion of the survival of, or axon regeneration in the neuron. | 2014-07-31 |
20140213610 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS - Compounds of Formula (I) | 2014-07-31 |
20140213611 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN - The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R | 2014-07-31 |
20140213612 | PPAR GAMMA AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS - Methods of treatment of multiple sclerosis (MS) with PPARγ agonists, and in particular with the compound of formula (I) known as INT131: | 2014-07-31 |
20140213613 | Novel Crystal Form - A novel crystalline form of a compound is disclosed. | 2014-07-31 |
20140213614 | Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation - The present invention is in the field of pharmaceuticals and chemical industries. In particular, the present invention relates to methods for labeling, imaging and detecting the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro by using carbazole-based fluorophores. A further aspect of the present invention relates to a method of reducing and preventing aggregation of beta-amyloid peptides for Alzheimer's disease (AD) as well as of treating and/or preventing Alzheimer's disease by using carbazole-based fluorophores. | 2014-07-31 |
20140213615 | Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof - The present invention provides materials and methods to induce cell death by methuosis, a non-apoptotic cell death mechanism, to induce vacuolization without cell death, or to induce cell death without vacuolization. Small molecules herein are useful for treating cell proliferation disorders or anomalies, particularly, but not exclusively, cancer. Methods related to the research and pharmaceutical use of the small molecules are also provided herein. | 2014-07-31 |
20140213616 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS - The invention relates to pyridone amide compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: | 2014-07-31 |
20140213617 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions. | 2014-07-31 |
20140213618 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO AND ANALOGUES THEREOF - The present invention provides compounds of formula (I): | 2014-07-31 |
20140213619 | PLANT DISEASE CONTROL COMPOSITION AND ITS USE - A composition comprising a carboxamide compound represented by following formula (I), wherein R | 2014-07-31 |
20140213620 | HISTONE DEACETYLASE INHIBITORS - In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors. These compounds include an ester bond making them sensitive to deactivation by esterases. Therefore, these compounds are particularly useful in the treatment of skin disorders. When the compounds reaches the bloodstream, an esterase or an enzyme with esterase activity cleaves the compound into biologically inactive fragments or fragments with greatly reduced activity Ideally these degradation products exhibit a short serum and/or systemic half-life and are eliminated rapidly. These compounds and pharmaceutical compositions thereof are particularly useful in treating cutaneous T-cell lymphoma, neurofibromatosis, psoriasis, hair loss, skin pigmentation, and dermatitis, for example. The present invention also provides methods for preparing compounds of the invention and intermediates thereto. | 2014-07-31 |
20140213621 | METHOD FOR TREATMENT OF CHRONIC NEUROPATHIC PAIN - Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors. | 2014-07-31 |
20140213622 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN AROMATSE INHIBITORS - The invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4′[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as therapeutic agents. | 2014-07-31 |
20140213623 | COMPOUNDS FOR TREATMENT OF CANCER - The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer. | 2014-07-31 |
20140213624 | METHOD FOR TREATING AND CURING LEISHMANIOSIS USING FEXINIDAZOLE - The present invention encompasses methods of using fexinidazole to treat and eliminate and/or cure | 2014-07-31 |
20140213625 | Methods and Compositions for Treating Foot or Hand Pain - The present disclosure provides novel formulations for treating foot or hand pain by topically administering a sympathomimetic drug, particularly oxymetazoline, to the skin of the foot or hand. | 2014-07-31 |
20140213626 | POLYMORPHS AND AMORPHOUS FORMS OF 5-AMINO-1-[2,6-DICHLORO-4-(TRIFLUOROMETHYL)PHENYL]-4-[(TRIFLUOROMETHYL)SU- LFINYL]-1H-PYRAZOLE-3-CARBONITRILE - The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoroethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents. | 2014-07-31 |
20140213627 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS - The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid. | 2014-07-31 |
20140213628 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEPSIS AND OTHER DISORDERS INVOLVING PHOSPHOLIPASE A2 INDUCTION - The present invention provides antisense oligomers to PLA | 2014-07-31 |
20140213629 | MOLECULAR TARGETS FOR HEALING OR TREATING WOUNDS - The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is PTPRK, or a protein 50% homologous therewith, and which retains the same activity as PTPRK protein. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds. | 2014-07-31 |
20140213630 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING LYMPHOID MALIGNANCY - The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity. | 2014-07-31 |
20140213631 | METHODS FOR MODULATING KALLIKREIN (KLKB1) EXPRESSION - Disclosed herein are methods for decreasing kallikrein and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to kallikrein include hereditary angioedema (HAE). Methods for inhibiting kallikrein can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema. | 2014-07-31 |
20140213632 | HCV Combination Therapy - The present invention relates to the treatment of hepatitis C (HCV) infection by the combination treatment with a miR-122 inhibitor and a HCV NS5A RNA protein inhibitor. | 2014-07-31 |
20140213633 | METHOD FOR PROLIFERATION CARDIOMYOCYTES USING MICRO-RNA - The present invention addresses the problems of providing a method for proliferating cardiomyocytes using a miRNA that promotes the proliferation of cardiomyocytes, a vector for use in the treatment of heart disease, a pharmaceutical composition for treating heart disease, and so forth. | 2014-07-31 |
20140213634 | METHOD FOR PROLIFERATION CARDIOMYOCYTES USING MICRO-RNA - The present invention addresses the problems of providing a method for proliferating cardiomyocytes using a miRNA that promotes the proliferation of cardiomyocytes, a vector for use in the treatment of heart disease, a pharmaceutical composition for treating heart disease, and so forth. | 2014-07-31 |
20140213635 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE - The invention relates to oligonucleotides for inducing skipping of exon 53 of the dystrophin gene. The invention also relates to methods of inducing exon 53 skipping using the oligonucleotides. | 2014-07-31 |
20140213636 | Method of treating hyperproliferation of cells using a nucleolin specific aptamer - Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided. | 2014-07-31 |
20140213637 | Agents for Improved Delivery of Nucleic Acids to Eukaryotic Cells - New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes. | 2014-07-31 |
20140213638 | Compositions and Biomarkers for Heart Disease, Injury and Failure and Methods of Use - The present disclosure provides biomarkers useful for determining the risk of, prognosis of, and/or diagnosis of conditions such as ischemic and/or non-ischemic heart failure in a subject. | 2014-07-31 |
20140213639 | Optimization of Vectors for Effective Delivery and Expression of Genetic Content - Lentiviral vectors, plates, kits and methods are provided that permit improved efficiency for selection of a promoter sequence for use in a lentiviral application. Through various embodiments of the present invention, a researcher may first evaluate and then choose in a modular fashion, a vector comprising a promoter that is effective for expression in a particular cell line or type. | 2014-07-31 |
20140213640 | VIRUS-LIKE PARTICLES FOR TREATMENT OF VIRAL INFECTIONS - The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus. | 2014-07-31 |
20140213641 | POLYMERIC NANOPARTICLES FOR DRUG DELIVERY - Disclosed are nanoparticles comprising a block copolymer and optionally one or more active agent(s), compositions comprising said nanoparticles and methods of preparing said nanoparticles. The block copolymer comprises blocks (i) a first polymer that is a polyester or polyamide and (ii) a second polymer comprising a hydrocarbon chain containing ester or ether bonds with hydroxyl number ≧10. The active agent(s) may be present within the nanoparticles or on the surfaces of the nanoparticles. The nanoparticles may optionally be associated with a surface-modifying moiety such that they are useful as drug delivery and molecular imaging devices. The surface-modifying moiety may target the nanoparticles to a desired target, cell, tissue or biomarker. | 2014-07-31 |
20140213642 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS - Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. | 2014-07-31 |
20140213643 | Long-acting nanoencapsulated arthropod repellent formulations and methods of use thereof - The present invention relates to novel nanoencapsulated compositions, methods for making such compositions, and methods of repelling insects and other arthropod pests away from animals, including humans. The present invention has particular, though not sole, application to repelling insects including flies and mosquitoes. The inventive compositions may be used to repel arthropods from animals, humans, plants, soil, or building structures. The formulations also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents. | 2014-07-31 |
20140213644 | Formulations and Methods for Prevention and Treatment of Oral Allergy Syndrome - A method and formulation for the prevention and treatment for Oral Allergy Syndrome (OAS), also referred to as Pollen-associated Food Allergy Syndrome (PFAS), is disclosed. The formulation significantly reduces or prevents symptoms related to Oral Allergy Syndrome while having a superb safety record. It can significantly improve Quality of Life for millions of patients afflicted with OAS. | 2014-07-31 |
20140213645 | THERMAL STABILIZATION OF IPBC BIOCIDE - A biocide, e.g. IPBC (3-iodo-2-propynl butylcarbamate), is stabilized against thermal degradation in matrix compositions which are processed at elevated temperatures, by blending the IPBC with a stabilizer additive, e.g. calcium stearate and/or a hindered phenol, alone or in combination therewith. | 2014-07-31 |
20140213646 | Sustained Release Formulations for the Treatment of Intraocular Pressure or Glaucoma - The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months. | 2014-07-31 |
20140213647 | COMPOUND USEFUL FOR PREVENTING OR TREATING IRRITABLE BOWEL SYNDROME AND COMPOSITION INCLUDING SAME - The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome. | 2014-07-31 |
20140213648 | METHODS OF INCREASING EPA BLOOD LEVELS - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2014-07-31 |
20140213649 | STABILIZED FORMULATION COMPRISING OMEGA-3 FATTY ACIDS AND USE OF THE FATTY ACIDS FOR SKIN CARE AND/OR WOUND CARE - A stabilized formulation for skin care, wound care and/or other tissue healing applications and methods for making the same is described. The stabilized formulation stabilizes omega-3 polyunsaturated fatty acids and is constituted of the omega-3 polyunsaturated fatty acids in combination with tocopherol (Vitamin E), ascorbic acid (Vitamin C), herb extract, and a fat-soluble antioxidant. Methods for making and using the stabilized formulation are also described. | 2014-07-31 |
20140213650 | Injectable Nitrogen Mustard Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same - The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same. | 2014-07-31 |
20140213651 | Novel Use of Adapalene in Treating Cancer - A novel use of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid or a pharmaceutically acceptable salt or functional derivative thereof in treating a cancer, and in particular non-small cell lung cancer, is provided. | 2014-07-31 |
20140213652 | METHODS OF SKIN WHITENENING BY USE OF CANOLA EXTRACTS - Compositions and methods for lightening skin are provided. A method for lightening skin may include the step of identifying skin where lightening or whitening is desired and topically applying to the skin a composition including (a) a skin lightening agent comprising a canola extract and (b) a cosmetically acceptable carrier. A method for treating hyperpigmentation may include the step of identifying skin containing areas of hyperpigmentation and topically applying to the skin a composition including (a) a canola extract and (b) a cosmetically acceptable carrier. | 2014-07-31 |
20140213653 | DIRECTLY COMPRESSIBLE PROPRIONIC ACID DERIVATIVE PARTICLES - A compressed tablet containing directly compressible propionic acid derivative particles is disclosed. A method of manufacturing a compressed tablet containing the directly compressible propionic acid derivative particles; and methods of treatment using the compressed tablet are also disclosed. | 2014-07-31 |
20140213654 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM - Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part. | 2014-07-31 |
20140213655 | METHOD OF TREATING STROKE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY - Methods for treating the animal central nervous system against the effects of stoke, including associated cognitive, behavioral and physical impairments. Effective amounts of therapeutic agents are administered to the upper third of the stroke patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO). | 2014-07-31 |
20140213656 | Plant Growth Regulator and Method for Using the Same - Provided is a novel plant growth regulator. The disclosed plant growth regulator comprises flubendiamide as an active ingredient. | 2014-07-31 |
20140213657 | LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE - The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH | 2014-07-31 |
20140213658 | TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME - The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof. | 2014-07-31 |
20140213659 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 2014-07-31 |
20140213660 | USE OF ((ETHOXY)HYDROXYPHENYL)ALKYL KETONE OR ETHOXYHYDROXYALKYLPHENOL COMPOUNDS FOR TREATING GREASY SKIN - The present invention relates to a cosmetic method for treating and/or preventing greasy skin or greasiness-prone skin and/or the associated cutaneous aesthetic defects, comprising the topical application to the skin of a composition comprising, in a cosmetically acceptable medium, at least one compound of formula (I): | 2014-07-31 |
20140213661 | HYDROPHILIC INTERPENETRATING POLYMER NETWORKS DERIVED FROM HYDROPHOBIC POLYMERS - A composition having a hydrogel bearing side of a biostable polymer network, wherein the biostable polymer network comprises a first gradient of the biostable polymer, which biostable polymer network decreases in concentration from the hydrogel bearing side to a bone interface surface; and a second gradient of a biostable polyurethane network, which polyurethane network increases in concentration from the hydrogel bearing side to the bone interface surface, the bone interface surface useful for an orthopedic implant. | 2014-07-31 |
20140213662 | PARTICLES WITH DESIGNED DIFFERENT SIZED DISCRETE PORES - Polymeric porous particles have a continuous solid phase and at least two sets of discrete pores that are isolated from each other within the continuous phase and that have different average sizes. One set of discrete pores has a larger average size than another set of discrete pores by at least 50%. At least one set of discrete pores is free of detectably different marker materials. There porous particles can be prepared using evaporative limited coalescence techniques with especially chosen discrete pore stabilizing hydrocolloids to protect the pores during formation and to provide the different average sizes. | 2014-07-31 |
20140213663 | ICE CRYSTALLIZATION INHIBITOR DERIVED FROM PLANT SEED - The objective to be solved by the present invention is to provide a novel ice crystallization inhibitor which is industrially useful, which can be efficiently and stably produced in a safe process suitable for a food production without difficulty and which has excellent functions and properties. Also, the objective of the present invention is to provide an antibody which specifically reacts with the ice crystallization inhibitor, and a composition, a food, a biological sample protectant and a cosmetic which contain the ice crystallization inhibitor. Furthermore, the objective of the present invention is to provide a peptide which gives an indication of a protein having an ice crystallization inhibitory activity. The ice crystallization inhibitor according to the present invention is characterized in comprising a seed protein derived from a plant belonging to genus | 2014-07-31 |
20140213664 | PROCESSES, PRODUCTS AND METHODOLOGIES FOR MAKING AND USING NOVEL BIOADVANTAGED SWEETENERS - Bioadvantaged Sweeteners leverage chemical synergies of combining select ratios of certain formulations of lactose and glucose with, for example, purified phlorizin for unexpectedly better results than predicted by prior art as a whole. Glucometer data confirms employing such Bioadvantaged Sweetener with conventional and enhanced delivery systems facilitates stasis at points of peak blood sugar saturation for users. | 2014-07-31 |
20140213665 | Process For Preparing Acylglycinates And Compositions Comprising Such Compounds - A process is described for preparing acylglycinates of the formula (I) wherein R | 2014-07-31 |
20140213666 | REACTION PRODUCT OF A POLAR MODIFIED POLYMER AND AN ALKOXYSILANE AND A COMPOSITION CONTAINING THE REACTION PRODUCT - The invention relates to a reaction product of a polar modified polymer and an alkoxysilane having at least one solubilizing functional group and at least one amino substituent. | 2014-07-31 |
20140213667 | METHOD OF PREVENTING AND TREATING AUTISTIC SPECTRUM DISORDER - A method of preventing and treating autistic spectrum disorder includes administration to a person of a product, which contains stable water clusters, such as stable double helix water clusters, by taking the products by mouth, applying the products on a skin of the person, intaking the product by breathing, introducing the products intravenously, etc. | 2014-07-31 |
20140213668 | ALKOXYLATED SORBITAN ESTERS AS CRUDE OIL EMULSION BREAKERS - Disclosed herein are alkoxylated sorbitan ester compounds and compositions useful in emulsion breaking applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed herein are methods of using the compounds and compositions as emulsion breakers, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. | 2014-07-31 |
20140213669 | FISCHER TROPSCH METHOD FOR OFFSHORE PRODUCTION RISERS FOR OIL AND GAS WELLS - A method and an apparatus is disclosed that uses a gas lift tubing arrangement to produce synthetic hydrocarbon related products. Using the Fischer Tropsch process as an example, the tubing is packed with a suitable catalyst and then hydrogen and carbon monoxide are injected into the top of the tubing in a fashion similar to a gas lift process. As the gases travel past the catalyst, synthetic hydrocarbons are formed and heat is rejected. The synthetic hydrocarbons and water flow out of the bottom of the tubing and travel up the annulus to the surface. In some embodiments, this process is carried out in a producing well or a in producing riser. In a producing well or a producing riser, the production from the well which flows up the annulus cools the synthetic hydrocarbon derived products. In additional and alternate embodiments, this process can be used in non-flowing wells. | 2014-07-31 |
20140213670 | HYBRID FISCHER-TROPSCH CATALYSTS AND PROCESSES FOR USE - Disclosed are hybrid Fischer-Tropsch catalysts containing cobalt and ZSM-48 zeolite. The hybrid Fischer-Tropsch catalysts can contain cobalt deposited on ZSM-48 extrudate supports. Alternatively, the Fischer-Tropsch catalysts can contain cobalt deposited on supports mixed with ZSM-48 particles. It has surprisingly been found that the use of hybrid Fischer-Tropsch catalysts containing ZSM-48 zeolite in synthesis gas conversion reactions results in improved C | 2014-07-31 |
20140213671 | AROMATIC SULFONIC ACID DERIVATIVE, SULFONIC ACID GROUP-CONTAINING POLYMER, BLOCK CO-POLYMER, POLYMER ELECTROLYTE MATERIAL, POLYMER ELECTROLYTE MOLDED BODY, AND SOLID POLYMER FUEL CELL - Provided are an aromatic sulfonic acid derivative and a sulfonic acid group-containing polymer, each of which has excellent proton conductivity even under low humidification conditions, while having excellent mechanical strength and chemical stability, and enables a solid polymer fuel cell to achieve high output and excellent physical durability when used therein. This aromatic sulfonic acid derivative has a specific structure and is characterized in that a sulfonic acid group is introduced into more than 50% of all the phenyl groups. This sulfonic acid group-containing polymer is characterized by being obtained by polymerization using the aromatic sulfonic acid derivative, and is also characterized by having a specific structure. | 2014-07-31 |
20140213672 | PHOSPHONIC ACID-CONTAINING BLENDS AND PHOSPHONIC ACID-CONTAINING POLYMERS - The invention relates to blends and blend membranes from low-molecular hydroxymethylene-oligo-phosphonic acids R—C(PO | 2014-07-31 |
20140213673 | RECYCLED POLYETHYLENE TEREPHTHALATE COMPOSITIONS, FIBERS AND ARTICLES PRODUCED THEREFROM, AND METHODS FOR PRODUCING SAME - In one aspect, the invention relates to recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same. In a further aspect, the invention relates to homogenized post-consumer polyethylene terephthalate. In a further aspect, the invention relates to extruded polymer compositions, polymer mixtures, fibers, and/or Bulked Continuous Filament fibers comprising post-consumer polyethylene terephthalate. In a further aspect, the invention relates to processes for preparing recycled polyethylene terephthalate compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2014-07-31 |
20140213674 | WATER EXPANDABLE POLYMER BEADS - The present invention relates to a process for the emulsifier-free preparation of water expandable polymer beads. The process comprises the steps of: a) providing an emulsifier-free monomer composition comprising styrene and a polar comonomer comprising a carbon-to-carbon double bond, b) prepolymerizing the monomer composition to obtain a prepolymer composition comprising styrene, the polar comonomer and their copolymer, c) adding an aqueous dispersion of nanoclay to the prepolymer composition to obtain an inverse emulsion, d) suspending the inverse emulsion obtained by step c) in an aqueous medium to yield an aqueous suspension of suspended droplets and e) polymerizing the monomers in the droplets of the suspension obtained by step d). | 2014-07-31 |
20140213675 | BIOPOLYMERIC MATERIAL INCLUDING MODIFIED NATURAL FIBRES AND THE METHOD FOR MANUFACTURING THE SAME - A method for producing a biopolymeric material includes milling a non-edible vegetable fiber into a fiber grain; mixing the fiber grain with a solvent to form a slurry; purifying the fiber grain of the slurry to form a purified fiber; esterifying the purified fiber to form an esterified fiber; drying the esterified fiber to form a modified fiber; and mixing the modified fiber with a plastic material to form the biopolymeric material. | 2014-07-31 |
20140213676 | FOAM MOLDING METHOD, FOAMING AGENT AND FOAMED PLASTIC - A foam molding method, a foamed plastic formed by the method, and a foaming agent used in the foam molding method are provided. The foam molding method may include rotating a screw provided in a barrel, feeding a granular or powdered raw material and a foaming agent into the barrel, the foaming agent producing foam through a chemical reaction, melting the fed raw material and producing a gas from the foaming agent, and phase-changing the produced gas to a supercritical state and mixing the gas with the melted raw material. | 2014-07-31 |
20140213677 | HYBRID POLYESTER-POLYETHER POLYOLS FOR IMPROVED DEMOLD EXPANSION IN POLYURETHANE RIGID FOAMS - The present invention discloses polyester-polyether polyols suitable for blending with other polyols or other materials mutually compatible with the polyester polyols to achieve polyurethane and polyisocyanurate products. In particular the present invention discloses polyester-polyether polyols produced by the reaction of: 1) phthalic anhydride with an alcohol having a nominal functionality of 3 and a molecular weight of 90 to 500 under conditions to form a phthalic anhydride half-ester; and 2) alkoxylating the half-ester formed in step 1 to form a polyester-polyether polyol having a hydroxyl number of from 200 to 350; with the proviso when the alcohol is a polyether polyol, the polyether polyol contains at least 70 weight percent of polyoxypropylene. | 2014-07-31 |
20140213678 | BLOWING AGENT COMPOSITIONS OF HYDROFLUOROOLEFINS AND HYDROCHLOROFLUOROOLEFINS - The present invention relates to blowing agent compositions comprising (1) at least one hydrofluoroolefin (HFO) and (2) at least one hydrochlorofluoroolefin (HCFO) used in the preparation of foamable thermoplastic compositions. The HFOs of component (1) include, but are not limited too, 3,3,3-trifluoropropene (HFO-1243zf), 1,2,3,3,3 -pentafluoropropene (HFO-1225ye), cis- and/or trans-1,3,33-tetrafluoropropene (HFO-1234ze), and 2,3,3,3-tetrafluoropropene (HFO 1234yf), and mixtures thereof. The HCFOs of component (2) include, but are not limited to, 1-chloro-3,3,3-trifluoropropene (HCFO-1233zd), 2-chloro-3,3,3-trifluoropropene (HCFO-1233xf) and mixtures thereof. The blowing agent compositions are useful in the production of low density insulating foams with improved k-factor. | 2014-07-31 |
20140213679 | EMULSIONS AND THEIR USE IN THE PRODUCTION OF FOAMS BASED ON ISOCYANATES - The invention relates to stable emulsions for the production of foams based on isocyanates, comprising at least three polyols A1a, A1b and A1c and at least one physical blowing agent T, wherein A1a is a polyether polyol, obtained by the addition of epoxies to starter compounds selected from carbohydrates and difunctional or higher-functional alcohols, A1b is a polyether polyol started on an aromatic amine and A1c is a polyester polyether polyol, obtained by the addition of epoxies to the esterification product of an aromatic dicarboxylic acid derivative and a difunctional or higher-functional alcohol. The invention further relates to a method for producing foams by reactions of such emulsions with isocyanates and to the foams obtainable in this way and their use for insulating purposes. | 2014-07-31 |
20140213680 | POLYSULFIDE POLYOLS, THEIR PRODUCTION AND USE - The present invention relates to polysulfide polyols, their production and use. | 2014-07-31 |
20140213681 | Method for Preparing Polycarbonate Resin - A method for preparing a polycarbonate resin includes polymerizing an aromatic dihydroxyl compound and a diaryl carbonate to prepare a polycarbonate pre-polymer; injecting and mixing an inert gas with the prepared polycarbonate pre-polymer; and foaming and polymerizing the polycarbonate pre-polymer with which the inert gas is mixed. The method can prevent or reduce yellowing upon melt polymerization of the polycarbonate resin. | 2014-07-31 |
20140213682 | CURABLE INKS COMPRISING DIURETHANE GELATORS - The disclosure provides curable inks including a diurethane gelator having the structure of Formula I. | 2014-07-31 |
20140213683 | SYNERGISTIC EFFECTS OF BLENDING MULTIPLE ADDITIVES IN UHMWPE - Oxidation resistant crosslinked ultrahigh molecular weight polyethylene (UHMWPE) is described, wherein at least two different additives in the manufacture synergistically increase the oxidation resistance of crosslinked UHMWPE. This allows the manufacture of oxidation resistant crosslinked UHMWPE using lower levels of additives and/or lower levels of crosslinking irradiation or chemicals. The lower levels of additives and/or crosslinking produce crosslinked UHMWPE having desired physical properties not possible without the synergistic interaction of the additives. This crosslinked UHMWPE may be used in medical prostheses such as in bearing components having desired physical properties such as wear resistance and oxidation resistance not possible without the synergistic interaction of the additives. | 2014-07-31 |